NZ's PHARMAC to award sole supply to Zoladex from AstraZeneca
New Zealand’s Pharmaceutical Management Agency PHARMAC has made decisions to award the Zoladex brand of cancer drug goserelin Sole Subsidized Supply in the community and Hospital Supply Status in District Health Board hospitals and to apply reference pricing to leuprorelin (Eligard and Lucrin) in the community.
In summary, the effect of the decisions is that:
- the price and subsidy for the Zoladex brand of goserelin (supplied by AstraZeneca (LSE: AZN]) will be reduced from October 1, 2016;
- the Zoladex brand of goserelin will be the community Sole Subsidized Supply brand and have Hospital Supply Status from December 1, 2016 until June 30, 2019. This means that Zoladex will be the only fully funded brand of goserelin in the community and will be the only available brand in DHB hospitals subject to a 1% discretionary variance (DV) Limit from December 1, 2016 until June 30, 2019;
- the subsidy for leuprorelin (Eligard, Lucrin) listed in Section B of the Pharmaceutical Schedule will be reduced to the level of subsidy of goserelin via the application of reference pricing from December 1, 2016. If the suppliers of leuprorelin do not reduce their prices to match the level of subsidy for goserelin, this would result in:
- a manufacturer’s surcharge applying to leuprorelin medicines; and
- goserelin being the only fully funded GnRH analogue.
- a higher subsidy by endorsement for leuprorelin will be available for children or adolescents who are unable to tolerate administration of goserelin;
- a higher subsidy by endorsement for leuprorelin will also be available from December 1, 2016 until February 28, 2017 for patients who have outstanding repeat dispensings of leuprorelin; and
- the four monthly dose presentation of leuprorelin inj 30mg, prefilled syringe (Eligard) will be delisted on October 1, 2016.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze